# A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

> **NCT05015920** · NA · COMPLETED · sponsor: **Shanghai BDgene Co., Ltd.** · enrollment: 2 (actual)

## Conditions studied

- Hematologic Diseases

## Interventions

- **GENETIC:** BD211 Drug Product

## Key facts

- **NCT ID:** NCT05015920
- **Lead sponsor:** Shanghai BDgene Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-10
- **Primary completion:** 2024-08-23
- **Final completion:** 2024-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05015920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05015920, "A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05015920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*